Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics
SEEL Price/Volume Stats
| Current price | $0.34 | 52-week high | $49.80 |
| Prev. close | $0.33 | 52-week low | $0.32 |
| Day low | $0.32 | Volume | 272,634 |
| Day high | $0.35 | Avg. volume | 433,322 |
| 50-day MA | $0.77 | Dividend yield | N/A |
| 200-day MA | $11.93 | Market Cap | 4.62M |
SEEL Stock Price Chart Interactive Chart >
Seelos Therapeutics, Inc. (SEEL) Company Bio
Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.
Latest SEEL News From Around the Web
Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.
Seelos Therapeutics, Inc. Releases Letter to its StockholdersSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below. |
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
Insider Spends US$100k Buying More Shares In Seelos TherapeuticsInvestors who take an interest in Seelos Therapeutics, Inc. ( NASDAQ:SEEL ) should definitely note that the Chief... |
Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)In the realm of stock market movements, insider trading can provide valuable insights into a company's health and future prospects. |
Seelos Therapeutics Announces Closing of Public OfferingSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. Each share of comm |
SEEL Price Returns
| 1-mo | -47.69% |
| 3-mo | -73.23% |
| 6-mo | -94.26% |
| 1-year | -98.59% |
| 3-year | -99.77% |
| 5-year | -99.61% |
| YTD | -75.54% |
| 2023 | -93.18% |
| 2022 | -58.34% |
| 2021 | 3.16% |
| 2020 | 17.91% |
| 2019 | -76.74% |
Loading social stream, please wait...